Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers

References

• WHO report on the global tobacco epidemic, 2009: implementing smoke-free environments. Geneva: World Health Organization, 2009
   Google Scholar
• Philippines’ Global Adult Tobacco Survey. Country Report Geneva: World Health Organization, 16 March 2010. Available at: http://www.wpro.who.int/internet/resources.ashx/TFI/2009GATSCountryReport_FinalPhilippines.pdf [Last accessed 1 April 2011]
   Google Scholar
• Philippines Global Youth Tobacco Survey (GYTS) 2007. Available at: http://tobaccocontrol.ph/wp-content/uploads/2011/02/2007-Philippines-GYTS-Factsheet.pdf [Last accessed 28 February 2011]
   Google Scholar
• Department of Health, Republic of the Philippines. Leading causes of morbidity 2010. Available at: http://www.doh.gov.ph/kp/statistics/morbidity.html [Last accessed 28 February 2011]
   Google Scholar
• Department of Health, Republic of the Philippines. Leading causes of mortality 2010. Available at: http://www.doh.gov.ph/kp/statistics/leading_mortality.html [Last accessed 28 February 2011]
   Google Scholar
• Philippines IMSH. Unpublished data
   Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8
   PubMed Web of Science ®Google Scholar
• Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008;32:664-75
   PubMed Web of Science ®Google Scholar
• Fagerström K, Nakamura M, Cho HJ, et al. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. Curr Med Res Opin 2010;26:2165-73
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose–response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39
   PubMed Web of Science ®Google Scholar
• Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92
   PubMed Web of Science ®Google Scholar
• Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211-17
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821-30
   PubMed Web of Science ®Google Scholar
• Ramon JM, Bruguera E. Real world study to evaluate the effectiveness of varenicline and cognitive–behavioural interventions for smoking cessation. Int J Environ Res Public Health 2009;6:1530-8
   PubMed Web of Science ®Google Scholar
• Halperin AC, McAfee TA, Jack LM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat 2009;36:428-34
   PubMed Web of Science ®Google Scholar
• Boudrez H, Gratziou C, Messig M, et al. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin 2011;27:769-75
   PubMed Web of Science ®Google Scholar
• Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009;32:499-507
   PubMed Web of Science ®Google Scholar